| Literature DB >> 34006336 |
Shui Shan Lee1, Denise Pui Chung Chan1, Ngai Sze Wong1, Grace Chung Yan Lui2, Kin Wang To2, Joseph Kai Man Kam1.
Abstract
Hong Kong is an intermediate tuberculosis (TB) burden city in Asia Pacific with slow decline of case notification in the last decade. By 24-loci mycobacterial interspersed repetitive units - variable number of tandem repeats genotyping, we examined 534 Mycobacterium tuberculosis isolates collected from culture-positive hospitalised TB patients in a 1.7 million population geographic region in the city. Overall, 286 (75%) were classified as Beijing genotype, of which 216 (76%) and 59 (21%) belonged to modern and ancient sub-lineage, respectively. Only two cases were genetically clustered while spatial clustering was absent. Male gender, permanent residency in Hong Kong and born in Hong Kong or Mainland China were associated with Beijing genotype. The high prevalence of Beijing modern lineage was similar to that in East Asia, which reflected the pattern resulting from population migration. The paucity of clustering suggested that reactivation accounted for most of the TB disease cases, which was and echoed by observation that half were 60 years old or above, and the presence of co-morbid medical conditions. The predominance of reactivation TB cases in intermediate burden localities implies that the detection and control of latent TB infection would be the major challenge in achieving TB elimination.Entities:
Keywords: Infectious disease control; molecular epidemiology; respiratory infections; tuberculosis (TB)
Year: 2021 PMID: 34006336 PMCID: PMC8193765 DOI: 10.1017/S0950268821001199
Source DB: PubMed Journal: Epidemiol Infect ISSN: 0950-2688 Impact factor: 2.451
Fig. 1.Minimum spanning tree based on the 24-MIRU-VNTR genotyping data of 382 MTB isolates from Hong Kong. The red circle denotes the non-Beijing family strain, while the green circle denotes the Beijing family strain.
Comparison between Beijing and non-Beijing genotype M. tuberculosis cases admitted to a major regional hospital in Hong Kong, 2015–2016 (n = 382)
| Non-Beijing ( | Beijing ( | Odds ratio (OR) | Adjusted OR (aOR) | |||||
|---|---|---|---|---|---|---|---|---|
| % | n | % | OR | (95% CI) | aOR | (95% CI) | ||
| Gender | ||||||||
| Female | 40 | 42% | 79 | 28% | ||||
| Male | 56 | 58% | 207 | 72% | 1.87 | (1.16–3.03) | / | |
| Age group (year-old) | ||||||||
| <35 | 18 | 19% | 41 | 14% | ||||
| 35–49 | 13 | 14% | 30 | 10% | 1.01 | (0.43–2.38) | 1.01 | (0.42–2.38) |
| 50–59 | 25 | 26% | 63 | 22% | 1.11 | (0.54–2.28) | 0.93 | (0.44–1.96) |
| 60–69 | 20 | 21% | 62 | 22% | 1.36 | (0.64–2.88) | 1.15 | (0.53–2.48) |
| 70–79 | 10 | 10% | 46 | 16% | 2.02 | (0.84–4.87) | 1.65 | (0.67–4.07) |
| ≥80 | 10 | 10% | 44 | 15% | 1.93 | (0.80–4.67) | 1.70 | (0.70–4.16) |
| Admission from LTCF | ||||||||
| No | 89 | 93% | 269 | 94% | ||||
| Yes | 7 | 7% | 17 | 6% | 0.80 | (0.32–2.00) | 0.77 | (0.30–1.92) |
| Birth place | ||||||||
| Hong Kong and China | 20 | 67% | 43 | 90% | ||||
| Others | 10 | 33% | 5 | 10% | 0.23 | (0.07–0.77) | 0.36 | (0.10–1.28) |
| Non-permanent residents | ||||||||
| No | 13 | 57% | 39 | 85% | ||||
| Yes | 10 | 43% | 7 | 15% | 0.23 | (0.07–0.74) | 0.27 | (0.08–0.94) |
| Smoking | ||||||||
| Non-smoker | 49 | 53% | 119 | 45% | ||||
| Ex-smoker | 25 | 27% | 74 | 28% | 1.22 | (0.69–2.14) | 0.78 | (0.40–1.54) |
| Current smoker | 19 | 20% | 72 | 27% | 1.56 | (0.85–2.86) | 1.05 | (0.52–2.10) |
| Alcohol | ||||||||
| Non-drinker | 55 | 65% | 163 | 66% | ||||
| Ex-drinker | 12 | 14% | 31 | 13% | 0.87 | (0.42–1.81) | 0.54 | (0.24–1.21) |
| Current drinker | 18 | 21% | 52 | 21% | 0.97 | (0.53–1.81) | 0.63 | (0.32–1.26) |
| Co-morbidities | ||||||||
| Cardiovascular diseases | 12 | 13% | 50 | 18% | 1.49 | (0.76–2.93) | 1.31 | (0.66–2.62) |
| Cancer | 18 | 19% | 36 | 13% | 0.62 | (0.34–1.16) | 0.55 | (0.29–1.04) |
| Chronic respiratory diseases | 9 | 9% | 33 | 12% | 1.26 | (0.58–2.74) | 1.09 | (0.50–2.41) |
| Diabetes | 20 | 21% | 82 | 29% | 1.53 | (0.88–2.66) | 1.43 | (0.81–2.50) |
| HIV infection | 0 | 0% | 2 | 1% | / | / | ||
| Type of TB | ||||||||
| Pulmonary | 67 | 70% | 202 | 71% | ||||
| Extrapulmonary | 28 | 29% | 75 | 26% | 0.89 | (0.53–1.49) | 1.01 | (0.60–1.72) |
| Both | 1 | 1% | 9 | 3% | 2.99 | (0.37–24.00) | 3.12 | (0.38–25.32) |
| TB drug resistance | ||||||||
| Isoniazid | 8 | 8% | 9 | 3% | 0.35 | (0.13–0.94) | 0.34 | (0.13–0.92) |
| Streptomycin | 7 | 7% | 29 | 10% | 1.42 | (0.6–3.35) | 1.36 | (0.57–3.24) |
| Rifampicin | 2 | 2% | 3 | 1% | 0.49 | (0.08–3.00) | 0.52 | (0.08–3.20) |
| Ethambutol | 0 | 0% | 2 | 1% | / | |||
| TB drug resistance (any) | ||||||||
| No | 86 | 91% | 253 | 88% | ||||
| Yes | 9 | 9% | 33 | 12% | 1.25 | (0.57–2.71) | 1.18 | (0.54–2.59) |
| Multidrug resistance | ||||||||
| No | 93 | 98% | 284 | 99% | ||||
| Yes | 2 | 2% | 2 | 1% | 0.33 | 0.05–2.36 | 0.36 | (0.05–2.67) |
P < 0.05.
Adjusted by gender in multivariable logistic regression.
1 missing.
37 missing.
92 missing.
Multidrug resistance refers to Isoniazid and Rifampicin resistance with/without other regimen resistance.